Figure and Table | Efficacy and Safety of Sitafloxacin in Treating Low-risk Febrile Neutropenia in Patients with Lung Cancer

Table 1. Personal and Clinical Characteristics of the Study Patients.

	N = 26
	Median or range
Sex	Male;19, Female;7
Age (years)	70.0 (50-82)
PS	0, 11; 1, 13; 2, 1; 3, 1; 4, 0
Creatinine (mg/dL)	0.93 (0.4-1.7)
Histology	Sm, 11; Ad, 11; Sq, 3; La, 1
Anticancer chemotherapy (line)	1^st, 12; 2^nd, 13; 3^rd, 1
Comorbidity	No; 13, Yes; 13
COPD	No, 26; Yes, 0
Smoking status	No, 7; Ever, 13; Current 6
Brinkman index	1200 (150-1820)
MASCC score	21.0 (21-24)

Table 2. Demographic and Clinical Characteristics of Febrile Neutropenia.

Table 3. Details of Adverse Events.